Further research is needed to verify whether the hepatic expression of adropin correlates with adropin circulating levels, and to investigate the extent to which changes in adropin have the potential to prevent or limit the metabolic and endocrine defects associated with fatty liver/NAFLD. The gene discussed is ENHO; the disease is metabolic dysfunction-associated steatotic liver disease.